Peritonitis carcinomatosa, indicating the presence of malignant cells in the peritoneal cavity, is a well- known complication of malignant disease. The collection of intraperitoneal fluid in a patient with ovarian cancer is most likely due to intraperitoneal spread of disease. The recognition of small quantities of intraperitoneal fluid may have staging and prognostic significance, while symptomatic large collections may reflect end-stage disease, which permits only palliative therapeutic options. In this paper we dis- cussed the pathogenesis of malignant ascites in ovarian cancer patients and suggested potential new treatment approaches
<zakljucak> Pri donosenju odluke o lecenju bolesnice sa karcinomom endometrijuma znacajno je: 1) da li je bolest u odmaklom stadijumu ili je prisutan recidiv tumora, 2) da li je prethodno sprovedena terapija i ako jeste, koji vid terapije (zracenje ili hemioterapija), 3) da li je tumor merljiv ili nemerljiv i 4) o kom se histoloskom tipu tumora radi. Kod pojave recidiva znacajno je da li se on javio u prethodno zracenom polju ili van njega. Treba imati u vidu da je prezivljavanje bolesnica sa odmaklim i recidivirajucim karcinomom endometrijuma oko jedne godine i da su dosadasnji protokoli pokazali manje ili vise izrazenu toksicnost. S tog aspekta, vazno je i da primenjena terapija ne izazove znacajno oboljenje i narusavanje kvaliteta zivota bolesnice. Terapija uznapredovalog, metastatskog i recidivirajuceg karcinoma endometrijuma zahteva individualni pristup u zavisnosti od zivotne dobi i opsteg stanja bolesnice, mesta recidiva i prethodno sprovedene terapije. Pored hemioterapije, terapijske mogucnosti koje su na raspolaganju za sada su palijativna hirurgija i radioterapija, kao i hormonska terapija. .
Numerous malignant diseases reach their incidence peak in female fertile years. That is the reason why these diseases are the second most common cause of death of women in their generative age. However, neoplastic processes are rarely diagnosed in pregnancy and there are no clear-cut guidelines on whether the pregnancy should be terminated in order that a proper treatment could be applied. We have not enough knowledge jet about the consequences for both the mother and her child if the pregnancy is allowed to continue despite the diagnosis of malignancy. Melanoma is one of the most common tumours diagnosed in pregnancy (8% of all diagnosed neoplasms). Some studies present the data on successfully terminated pregnancies in these women but also point out the risks the fetus is exposed to due to possible application of cytotoxic therapy, as well as the danger of transplacental spread of this process to the placenta and fetus
Imiquimod is a local immunomodulator with antiviral effects. Vulvar intraepithelial neoplasia is a chronic precancerous condition of the skin of the vulva, with different malignant potential and clinical course. The aim of the paper was to determine therapeutic effects of Imiquimod in treating different types and grades of vulvar intraepithelial neoplasms. The study enrolled 17 patients with vulvar pre-cancerous conditions of different grade and histological type. The patients were treated with combined medical therapy oral systemic immunomodulatory and antiviral drug-inosine acedoben dimepranol and 5% Imiquimod cream locally applied to the lesion area using cotton swabs. Complete remision (CR) had 41.18% of patients, partial remission (PR) was seen in 47.06%, and 11.76% of patients had no response (NR). Out of these patients, response distribution for usual type was: CR 80%, 20% NR, and for differentiated type the response distribution was: 8.3% NR, 66.67% PR, while 25% of patients had CR. The use of imiquimod for conservative treatment of vulvar intraepithelial neoplasia is a beneficial alternative to surgical treatment. The best results of imiquimod treatment are achieved in younger patients with usual type of vulvar neoplasia, while the treatment effects are limited to partial response in older patients with differentiated VIN.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.